VCYT

VERACYTE, INC.

Nasdaq · Services-Medical Laboratories · Inc. DE · CIK 0001384101

$47.27 -3.00% $3.8B

Insider Selling Cluster (6 insiders)High Impact Filing (8/10)

Vol

Market Cap$3.8B

Cap SizeMid Cap

Analyst ConsensusStrong Buy (83%)

Inst. Holders6 funds

Inst. Value$745.1M

Inst. Activity2 buys / 1 sells

Insider Activity0B / 11S

Insider Net $-$10.7M

SEC Reports8

Exchange Nasdaq·Sector Services-Medical Laboratories·Inc. DE·CIK 0001384101·Prev Close $48.73

Recent Activity

Jun 5, 2026 SEC

Insider selling cluster at Veracyte: CEO Marc Stapley sold 138,051 shares for $6.9M and Global Chief Commercial Officer

CLUSTER — Impact 4/10

Jun 4, 2026 Insider

Stapley Marc sold 138,051 shares

Chief Executive Officer @ $36.60 ($5.1M)

Jun 4, 2026 Insider

Stapley Marc sold 138,051 shares

Chief Executive Officer @ $50.12 ($6.9M)

Jun 4, 2026 Insider

Stapley Marc sold 138,051 shares

Chief Executive Officer @ $0.00 ($0.00)

May 27, 2026 SEC

Two insiders at Veracyte sold a total of $1.53M in open-market sales over a 7-day window. The VP and Chief Accounting Of

CLUSTER — Impact 3/10

May 20, 2026 SEC

Director Robert Epstein filed a Form 144 on May 20, 2026, indicating intent to sell 10,000 common shares (~$417K at fili

144 — Impact 2/10

Inst.

MORGAN STANLEY — ADD

1,183,069 shares ($49.8M)

Inst.

WELLS FARGO & COMPANY/MN — ADD

98,506 shares ($4.1M)

Price Targets

$49.10 -0.3% upside Hold

Current $49.24 Low $37.00 Median $50.50 High $57.00 10 analysts

$37.00 $57.00

Analyst Ratings

Strong Buy83% buy · 18 analysts

8Strong Buy

7Buy

2Hold

1Sell

0Strong Sell

Recent Analyst Actions

Date	Firm	Action	Rating
Jun 1, 2026	Needham	MAINTAIN	Buy → Buy
May 28, 2026	Needham	REITERATE	Buy → Buy
May 6, 2026	Canaccord Genuity	MAINTAIN	Hold → Hold
May 6, 2026	UBS	MAINTAIN	Buy → Buy
Apr 20, 2026	Canaccord Genuity	MAINTAIN	Hold → Hold

Earnings Estimates

Period	EPS Est.	Range	Growth	#
Current Q	$0.43 ▲ +3.3%	$0.40 — $0.47	-2% YoY	10
Next Q	$0.43 ▼ -0.6%	$0.38 — $0.47	-15% YoY	10
Current FY	$1.82 ▲ +10.5%	$1.71 — $1.95	2% YoY	10
Next FY	$1.90 ▲ +7.7%	$1.74 — $2.10	4% YoY	10

Latest Reports

NEUTRAL CLUSTER 4/10

Insider selling cluster at Veracyte: CEO Marc Stapley sold 138,051 shares for $6.9M and Global Chief Commercial Officer

Jun 5, 2026

NEUTRAL CLUSTER 3/10

Two insiders at Veracyte sold a total of $1.53M in open-market sales over a 7-day window. The VP and Chief Accounting Of

May 27, 2026

Top Institutional Holders

Fund	Value	Move
VANGUARD GROUP INC	$358.0M	—
FMR LLC	$241.6M	DOUBLED
BANK OF AMERICA CORP	$53.2M	ADD
MORGAN STANLEY	$49.8M	ADD
CHARLES SCHWAB INVESTMENT MANAGEMENT	$38.3M	NEW

Recent Insider Trades

Date	Insider	Type	Value
Jun 4, 2026	Stapley Marc	M	$5.1M
Jun 4, 2026	Stapley Marc	SELL	$6.9M
Jun 4, 2026	Stapley Marc	M	$0.00
Jun 4, 2026	Leite John	SELL	$699.7K
Jun 4, 2026	Chambers Rebecca	SELL	$78.9K

6 institutional holders with $745.1M total value (17,697,592 shares) as of 2025-Q4. Top holders: VANGUARD, FMR, BANK. Net buying activity: 2 institutions added/increased vs 1 reduced.

Top Institutional Holders — 2025-Q4

#	Fund	Shares	Value	% of Tracked	Last Move
1	VANGUARD GROUP INC	8,504,011	$358.0M	48.1%	—
2	FMR LLC	5,738,209	$241.6M	32.4%	DOUBLED +240.9%
3	BANK OF AMERICA CORP /DE/	1,262,968	$53.2M	7.1%	ADD +31.1%
4	MORGAN STANLEY	1,183,069	$49.8M	6.7%	ADD +31.5%
5	CHARLES SCHWAB INVESTMENT MANAGEMENT INC	910,829	$38.3M	5.1%	NEW
6	WELLS FARGO & COMPANY/MN	98,506	$4.1M	0.6%	ADD +73.5%

Recent Position Changes

Fund	Action	Prev Shares	Curr Shares	Change %	Value	Quarter
MORGAN STANLEY	ADD	899,978	1,183,069	+31.5%	$49.8M	2025-Q4
WELLS FARGO & COMPANY/MN	ADD	56,771	98,506	+73.5%	$4.1M	2025-Q4
RENAISSANCE TECHNOLOGIES LLC	EXIT	72,584	0	-100.0%	$0.00	2025-Q4
RENAISSANCE TECHNOLOGIES LLC	NEAR_EXIT	610,400	72,584	-88.1%	$2.5M	2025-Q3
NORGES BANK	EXIT	43,816	0	-100.0%	$0.00	2025-Q3
BANK OF AMERICA CORP /DE/	ADD	1,158,763	1,519,710	+31.1%	$41.1M	2025-Q2
MORGAN STANLEY	ADD	526,586	788,977	+49.8%	$21.3M	2025-Q2
RENAISSANCE TECHNOLOGIES LLC	TRIM	832,000	610,400	-26.6%	$16.5M	2025-Q2
NORGES BANK	NEW	—	43,816	—	$1.2M	2025-Q2
FMR LLC	DOUBLED	2,082,723	7,100,451	+240.9%	$210.5M	2025-Q1
RENAISSANCE TECHNOLOGIES LLC	ADD	600,700	832,000	+38.5%	$24.7M	2025-Q1
CITADEL ADVISORS LLC	NEAR_EXIT	306,600	61,075	-80.1%	$1.8M	2025-Q1
NORGES BANK	EXIT	225,602	0	-100.0%	$0.00	2025-Q1
UBS Group AG	ADD	180,772	314,047	+73.7%	$12.4M	2024-Q4
CITADEL ADVISORS LLC	TRIM	508,973	306,600	-39.8%	$12.1M	2024-Q4
WELLS FARGO & COMPANY/MN	ADD	39,744	51,131	+28.7%	$2.0M	2024-Q4
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	NEW	—	735,007	—	$25.0M	2024-Q3
MORGAN STANLEY	ADD	475,381	710,588	+49.5%	$24.2M	2024-Q3

8 unique insiders with 11 transactions. Net insider value: -$10.7M ($0.00 bought, $10.7M sold).

Insider Transactions

Date	Insider	Title	Type	Shares	Price	Value
Jun 4, 2026	Stapley Marc	Chief Executive Officer	M	138,051	$36.60	$5.1M
Jun 4, 2026	Stapley Marc	Chief Executive Officer	SELL	138,051	$50.12	$6.9M
Jun 4, 2026	Stapley Marc	Chief Executive Officer	M	138,051	$0.00	$0.00
Jun 4, 2026	Leite John	Global Chief Commercial Off	SELL	13,975	$50.07	$699.7K
Jun 4, 2026	Chambers Rebecca	Chief Financial Officer	SELL	1,600	$49.28	$78.9K
Jun 4, 2026	McGuire Annie	EVP, General Counsel	SELL	1,400	$49.31	$69.0K
Jun 2, 2026	Febbo Phillip G.	Chief Scientific & Med Officer	F	3,730	$47.80	$178.3K
Jun 2, 2026	Stapley Marc	Chief Executive Officer	F	9,012	$47.80	$430.8K
Jun 2, 2026	Chambers Rebecca	Chief Financial Officer	F	3,693	$47.80	$176.5K
Jun 2, 2026	Leite John	Global Chief Commercial Off	F	4,059	$47.80	$194.0K
Jun 2, 2026	Wygant Jonathan	VP, Chief Accounting Officer	F	1,361	$47.80	$65.1K
Jun 2, 2026	McGuire Annie	EVP, General Counsel	F	3,292	$47.80	$157.4K
May 22, 2026	Wygant Jonathan	VP, Chief Accounting Officer	M	24,000	$24.80	$595.2K
May 22, 2026	Wygant Jonathan	VP, Chief Accounting Officer	SELL	24,000	$45.40	$1.1M
May 22, 2026	Wygant Jonathan	VP, Chief Accounting Officer	M	24,000	$0.00	$0.00
May 20, 2026	EPSTEIN ROBERT S	Director	SELL	10,000	$44.01	$440.1K
May 6, 2026	McGuire Annie	SVP, General Counsel	SELL	5,102	$38.05	$194.1K
Apr 10, 2026	Haas Kevin Richard	Chief Dev and Tech Officer	A	44,221	$0.00	$0.00
Mar 6, 2026	McGuire Annie	SVP, General Counsel	A	32,892	$0.00	$0.00
Mar 6, 2026	Stapley Marc	Chief Executive Officer	A	92,099	$0.00	$0.00
Mar 6, 2026	Wygant Jonathan	VP, Chief Accounting Officer	A	10,525	$0.00	$0.00
Mar 6, 2026	Febbo Phillip G.	Chief Scientific & Med Officer	A	29,603	$0.00	$0.00
Mar 6, 2026	Chambers Rebecca	Chief Financial Officer	A	36,181	$0.00	$0.00
Mar 6, 2026	Leite John	Chief Commercial Officer-CLIA	A	36,181	$0.00	$0.00
Mar 4, 2026	Leite John	Chief Commercial Officer-CLIA	SELL	5,260	$35.19	$185.1K
Mar 4, 2026	McGuire Annie	SVP, General Counsel	SELL	4,994	$35.29	$176.3K
Mar 4, 2026	Chambers Rebecca	Chief Financial Officer	SELL	4,400	$35.55	$156.4K
Mar 4, 2026	Stapley Marc	Chief Executive Officer	SELL	19,244	$35.56	$684.2K
Mar 2, 2026	Wygant Jonathan	VP, Chief Accounting Officer	F	3,006	$36.01	$108.2K
Mar 2, 2026	Chambers Rebecca	Chief Financial Officer	F	7,234	$36.01	$260.5K
Mar 2, 2026	Stapley Marc	Chief Executive Officer	F	19,455	$36.01	$700.6K
Mar 2, 2026	McGuire Annie	SVP, General Counsel	F	6,902	$36.01	$248.5K
Mar 2, 2026	Febbo Phillip G.	Chief Scientific & Med Officer	F	6,035	$36.01	$217.3K
Mar 2, 2026	Leite John	Chief Commercial Officer-CLIA	F	7,517	$36.01	$270.7K
Feb 26, 2026	McGuire Annie	SVP, General Counsel	A	50,999	$0.00	$0.00
Feb 26, 2026	Febbo Phillip G.	Chief Scientific & Med Officer	A	71,806	$0.00	$0.00
Feb 26, 2026	Stapley Marc	Chief Executive Officer	A	139,074	$0.00	$0.00
Feb 26, 2026	Leite John	Chief Commercial Officer-CLIA	A	47,149	$0.00	$0.00
Feb 26, 2026	Chambers Rebecca	Chief Financial Officer	A	59,324	$0.00	$0.00

8 SEC filing reports analyzed. Sentiment: 2 bullish, 1 bearish, 0 mixed, 5 neutral. Avg impact: 4.8/10.

NEUTRAL CLUSTER 4/10

Insider selling cluster at Veracyte: CEO Marc Stapley sold 138,051 shares for $6.9M and Global Chief

Jun 5, 2026

NEUTRAL CLUSTER 3/10

Two insiders at Veracyte sold a total of $1.53M in open-market sales over a 7-day window. The VP and

May 27, 2026

NEUTRAL 144 2/10

Director Robert Epstein filed a Form 144 on May 20, 2026, indicating intent to sell 10,000 common sh

May 20, 2026

BULLISH 8-K 8/10

Veracyte reported Q1 2026 earnings with total revenue of $139.1M (+21% YoY) and GAAP diluted EPS of

May 5, 2026

NEUTRAL DEFA14A 3/10

Verae Technologies, Inc. (VCYT) filed a definitive additional proxy materials (DEFA14A) notice ahead

Apr 22, 2026

BEARISH CLUSTER 6/10

Multiple C-suite executives at Veracyte sold shares in a coordinated open-market transaction cluster

Mar 10, 2026

NEUTRAL CLUSTER 4/10

Multiple executives at Veracyte sold shares in a concentrated 7-day window, including $1.2M in open-

Mar 6, 2026

BULLISH 8-K 8/10

Veracyte reported strong fourth quarter and full year 2025 financial results, with Q4 total revenue

Feb 25, 2026

∅

No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.

Current analyst consensus: Strong Buy (83% buy). Based on 18 analysts: 8 strong buy, 7 buy, 2 hold, 1 sell, 0 strong sell.

Analyst Price Targets

$49.10 mean target -0.3% upside Hold (1.64)

$37.00 Low $57.00 High

Metric	Value
Current Price	$49.24
Target Low	$37.00
Target Mean	$49.10
Target Median	$50.50
Target High	$57.00
# Analysts	10
Recommendation	Hold (1.64)

Earnings Estimates & Revisions

Period	EPS Avg	EPS Low	EPS High	EPS Growth	30d Rev.	Up/Down	Rev. Avg	Rev. Growth	Analysts
Current Q 2026-06-30	$0.43	$0.40	$0.47	-1.6%	+3.3%	6↑ 0↓	$0.1B	11.0%	10
Next Q 2026-09-30	$0.43	$0.38	$0.47	-15.1%	-0.6%	3↑ 3↓	$0.1B	12.7%	10
Current FY 2026-12-31	$1.82	$1.71	$1.95	2.3%	+10.5%	6↑ 0↓	$0.6B	13.3%	10
Next FY 2027-12-31	$1.90	$1.74	$2.10	4.4%	+7.7%	6↑ 0↓	$0.7B	11.6%	10

Current Quarter EPS Revision History

Timepoint	EPS Estimate	Change
Current	$0.433
7d ago	$0.435	-0.002
30d ago	$0.419	+0.014
60d ago	$0.417	+0.016
90d ago	$0.412	+0.021

6 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.

Individual Analyst Actions

Date	Analyst Firm	Action	Previous Rating	New Rating
Jun 1, 2026	Needham	MAINTAIN	Buy	Buy
May 28, 2026	Needham	REITERATE	Buy	Buy
May 6, 2026	Canaccord Genuity	MAINTAIN	Hold	Hold
May 6, 2026	UBS	MAINTAIN	Buy	Buy
Apr 20, 2026	Canaccord Genuity	MAINTAIN	Hold	Hold
Apr 13, 2026	Jefferies	INITIATE	—	Buy
Apr 1, 2026	Needham	MAINTAIN	Buy	Buy
Mar 30, 2026	Guggenheim	MAINTAIN	Buy	Buy
Mar 6, 2026	Morgan Stanley	MAINTAIN	Underweight	Underweight
Feb 26, 2026	Needham	MAINTAIN	Buy	Buy
Jan 5, 2026	Guggenheim	MAINTAIN	Buy	Buy

Monthly Consensus History

Period	Strong Buy	Buy	Hold	Sell	Buy %
Jun 1, 2026	8	7	2	1	83%
May 1, 2026	8	8	2	1	84%
Apr 1, 2026	7	8	3	1	79%
Mar 1, 2026	7	8	3	1	79%
Feb 1, 2026	7	8	3	1	79%
Jan 1, 2026	7	8	3	1	79%

Strong BuyBuyHoldSellStrong Sell

∅

No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.

∅

No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.

May 18, 2026

short_volume

Short Volume: VCYT — 64.2% short (0.4M / 0.6M)

Short: 375,762 | Exempt: 111 | TRF Vol: 585,040 | Short Ratio: 64.2% | Off-exchange volume (dark pool + OTC)

May 8, 2026

short_interest

FTD: VCYT — 116,620 shares ($4.8M) failed to deliver

Settlement: 20260508, Price: $40.76, FTD Value: $4,753,431.2, VERACYTE INC COM

May 7, 2026

short_volume

Short Volume: VCYT — 79.7% short (0.5M / 0.7M)

Short: 529,938 | Exempt: 97,565 | TRF Vol: 665,273 | Short Ratio: 79.7% | Off-exchange volume (dark pool + OTC)

May 5, 2026

short_volume

Short Volume: VCYT — 73.0% short (0.4M / 0.5M)

Short: 378,928 | Exempt: 0 | TRF Vol: 519,247 | Short Ratio: 73.0% | Off-exchange volume (dark pool + OTC)

May 5, 2026

earnings_calendar

VCYT Q1 2026 Earnings After Market Close — 2026-05-05

Feb 25, 2026

earnings_calendar

VCYT Q4 2025 Earnings After Market Close — 2026-02-25